NASDAQ:DRRX DURECT - DRRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. $5.80 -0.60 (-9.38%) (As of 02/6/2023 05:33 PM ET) Add Compare Share Share Today's Range$5.65▼$6.2850-Day Range$3.39▼$8.7252-Week Range$3.16▼$9.70Volume260,829 shsAverage Volume112,935 shsMarket Capitalization$132.18 millionP/E RatioN/ADividend YieldN/APrice Target$32.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability DURECT MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside452.7% Upside$32.00 Price TargetShort InterestBearish1.43% of Float Sold ShortDividend StrengthN/ASustainability-1.19Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.62) to ($1.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.36 out of 5 starsMedical Sector968th out of 1,027 stocksPharmaceutical Preparations Industry469th out of 500 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $32.00, DURECT has a forecasted upside of 452.7% from its current price of $5.79.Amount of Analyst CoverageDURECT has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.43% of the float of DURECT has been sold short.Short Interest Ratio / Days to CoverDURECT has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in DURECT has recently increased by 2.91%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDURECT does not currently pay a dividend.Dividend GrowthDURECT does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDURECT has received a 67.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for DURECT is -1.19. Previous Next 1.2 News and Social Media Coverage News SentimentDURECT has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.Search InterestOnly 5 people have searched for DRRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DURECT insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.50% of the stock of DURECT is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for DURECT are expected to decrease in the coming year, from ($1.62) to ($1.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DURECT is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DURECT is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDURECT has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DURECT (NASDAQ:DRRX) StockDURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.Read More Receive DRRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter. Email Address DRRX Stock News HeadlinesJanuary 15, 2023 | fool.comDurect (NASDAQ: DRRX)January 1, 2023 | reuters.comDRRX.C - DURECT Corp | Stock Price & Latest News | ReutersFebruary 6, 2023 | Investing Trends (Ad)New "Vertical" Technology Solves Solar Power's Major FlawEven conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.December 17, 2022 | finance.yahoo.comDURECT Corporation (DRRX) Stock Historical Prices & Data - Yahoo FinanceDecember 4, 2022 | finanznachrichten.deDURECT Corporation: DURECT Announces 1-for-10 Reverse Stock SplitNovember 28, 2022 | finance.yahoo.comDURECT Announces 1-for-10 Reverse Stock SplitNovember 25, 2022 | americanbankingnews.comDURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.comNovember 2, 2022 | finance.yahoo.comDURECT Corporation Reports Third Quarter 2022 Financial Results and Update of ProgramsFebruary 6, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...October 26, 2022 | finance.yahoo.comDURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2October 17, 2022 | finance.yahoo.com$103+ Billion Worldwide Biomaterials Industry to 2031 - North America was the Largest Region in 2021 - Yahoo FinanceOctober 10, 2022 | reuters.comDRRX.OQ - DURECT Corp | Stock Price & Latest News | ReutersOctober 6, 2022 | finance.yahoo.comDURECT Reaches Enrollment Milestone in Phase 2b AHFIRM TrialSeptember 28, 2022 | nasdaq.comInnocoll To Make $2 Mln Payment To DURECT On First Commercial Sale Of POSIMIRSeptember 26, 2022 | nasdaq.comHealth Care Sector Update for 09/26/2022: SGEN,LVTX,AMEH,SIGA,DRRX - NasdaqSeptember 26, 2022 | finance.yahoo.comInnocoll and DURECT Announce U.S. launch of POSIMIR®September 13, 2022 | streetinsider.comForm 8-K ProMIS Neurosciences For: Sep 12 - StreetInsider.comSeptember 6, 2022 | benzinga.comDurect (DRRX) – DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference - BenzingaAugust 23, 2022 | msn.comDurect's Return On Capital Employed Insights - msnNOWAugust 23, 2022 | benzinga.comDurect's Return On Capital Employed Insights - BenzingaAugust 12, 2022 | benzinga.com$1.7 Million Bet On Offerpad Solutions? Check Out These 3 Penny Stocks Insiders Are Buying - BenzingaAugust 8, 2022 | finance.yahoo.comRainbows and Unicorns: DURECT Corporation (NASDAQ:DRRX) Analysts Just Became A Lot More Optimistic - Yahoo FinanceAugust 8, 2022 | finance.yahoo.comRainbows and Unicorns: DURECT Corporation (NASDAQ:DRRX) Analysts Just Became A Lot More OptimisticAugust 5, 2022 | benzinga.comWhy Is Marker Therapeutics Trading Higher By 119%: Here Are 42 Stocks Moving Premarket - BenzingaAugust 5, 2022 | benzinga.comWhy Cooper-Standard Is Trading Higher By 70%, Here Are 81 Stocks Moving In Friday’s Mid-Day Session - BenzingaAugust 5, 2022 | finance.yahoo.comDURECT Corporation Reports Second Quarter 2022 Financial Results and Update of Programs - Yahoo FinanceAugust 5, 2022 | seekingalpha.comDurect GAAP EPS of -$0.05, revenue of $2.08M (NASDAQ:DRRX) - Seeking AlphaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DRRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter. Email Address DRRX Company Calendar Last Earnings11/01/2021Today2/06/2023Next Earnings (Estimated)3/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRRX CUSIPN/A CIK1082038 Webwww.durect.com Phone(408) 777-1417Fax408-777-3577Employees79Year FoundedN/APrice Target and Rating Average Stock Price Forecast$32.00 High Stock Price Forecast$32.00 Low Stock Price Forecast$32.00 Forecasted Upside/Downside+451.7%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($1.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,260,000.00 Net Margins-136.99% Pretax Margin-136.99% Return on Equity-72.05% Return on Assets-41.00% Debt Debt-to-Equity Ratio0.51 Current Ratio4.44 Quick Ratio4.27 Sales & Book Value Annual Sales$13.98 million Price / Sales9.46 Cash FlowN/A Price / Cash FlowN/A Book Value$2.54 per share Price / Book2.28Miscellaneous Outstanding Shares22,790,000Free Float21,761,000Market Cap$132.18 million OptionableOptionable Beta1.40 Key ExecutivesJames E. BrownPresident, Chief Executive Officer & DirectorJudy R. JoiceSenior VP-Operations & Corporate Quality AssuranceTimothy M PappChief Financial Officer & SecretaryWei Qi LinExecutive Vice President-Research & DevelopmentDavid J. EllisVice President-Clinical DevelopmentKey CompetitorsFrequency TherapeuticsNASDAQ:FREQTrevi TherapeuticsNASDAQ:TRVIAnixa BiosciencesNASDAQ:ANIXAesther Healthcare AcquisitionNASDAQ:AEHAMilestone PharmaceuticalsNASDAQ:MISTView All CompetitorsInsiders & InstitutionsCowen Prime Advisors LLCSold 81,257 shares on 2/1/2023Ownership: 0.206%Ingalls & Snyder LLCSold 8,209,573 shares on 1/31/2023Ownership: 4.015%Ironwood Investment Management LLCSold 768,096 shares on 1/31/2023Ownership: 0.366%Regis Management CO LLCSold 120,825 shares on 1/26/2023Ownership: 0.059%DAVENPORT & Co LLCSold 150,075 shares on 1/20/2023Ownership: 0.073%View All Insider TransactionsView All Institutional Transactions DRRX Stock - Frequently Asked Questions What is DURECT's stock price forecast for 2023? 0 Wall Street research analysts have issued 1-year price objectives for DURECT's stock. Their DRRX share price forecasts range from $32.00 to $32.00. On average, they predict the company's stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 451.7% from the stock's current price. View analysts price targets for DRRX or view top-rated stocks among Wall Street analysts. How have DRRX shares performed in 2023? DURECT's stock was trading at $3.46 at the beginning of the year. Since then, DRRX shares have increased by 67.6% and is now trading at $5.80. View the best growth stocks for 2023 here. When is DURECT's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023. View our DRRX earnings forecast. How were DURECT's earnings last quarter? DURECT Co. (NASDAQ:DRRX) released its quarterly earnings data on Monday, November, 1st. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10. The specialty pharmaceutical company earned $2.17 million during the quarter, compared to the consensus estimate of $2.18 million. DURECT had a negative net margin of 136.99% and a negative trailing twelve-month return on equity of 72.05%. During the same quarter last year, the company earned ($0.50) earnings per share. When did DURECT's stock split? DURECT shares reverse split on the morning of Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of DURECT own? Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM). What is DURECT's stock symbol? DURECT trades on the NASDAQ under the ticker symbol "DRRX." Who are DURECT's major shareholders? DURECT's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (4.01%), Ironwood Investment Management LLC (0.37%), Cowen Prime Advisors LLC (0.21%), DAVENPORT & Co LLC (0.07%), Regis Management CO LLC (0.06%) and Merit Financial Group LLC (0.04%). Insiders that own company stock include Gail J Maderis, Gail M Farfel, Judith J Robertson, Judy R Joice, Lp Bleichroeder, Mohammad Azab and Simon X Benito. View institutional ownership trends. How do I buy shares of DURECT? Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DURECT's stock price today? One share of DRRX stock can currently be purchased for approximately $5.80. How much money does DURECT make? DURECT (NASDAQ:DRRX) has a market capitalization of $132.18 million and generates $13.98 million in revenue each year. The specialty pharmaceutical company earns $-36,260,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. How can I contact DURECT? DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The official website for the company is www.durect.com. The specialty pharmaceutical company can be reached via phone at (408) 777-1417, via email at mike.arenberg@durect.com, or via fax at 408-777-3577. This page (NASDAQ:DRRX) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.